Obsessive-compulsive disorder (OCD) is characterized by the presence of obsessions and/or compulsions. It is a leading cause of morbidity worldwide, as it can interfere with all aspects of life. Despite the adequate treatment trials, half of patients preserve residual or impairing symptoms and selective serotonin reuptake inhibitors (SSRIs) are not free from adverse side effects.
Introduction
Obsessive-compulsive disorder (OCD) is characterized by the presence of obsessions and/or compulsions (American Psychiatric Association, 2013) . Obsessions are recurrent, persistent, distressing thoughts, mental images, or impulses that are experienced as intrusive and unwanted. Patients with OCD try to neutralize the anxiety and discomfort from the obsessions with compulsions (American Psychiatric Association, 2013) . Compulsions are repetitive behaviors or mental acts that a person with OCD feels the urge to do in response to an obsessive thought. Compulsive symptomatology is typically associated with hygiene, orderliness, checking, grooming, and hoarding (Brüne, 2015) . Some authors proclaim that performing compulsions when obsessions recur leads to reinforcement and repetitive behavior, due to the transitory relief of stress (Saxena and Rauch, 2000) . Another perspective is that OCD obsessions and compulsions represent the pathological extremes of adaptive processes that are concerned with risk aversion (Brüne, 2015) .
OCD is a leading cause of morbidity worldwide with 1.1%-1.8% annual prevalence (American Psychiatric Association, 2013 ) and 2%-3% lifetime prevalence (Ruscio et al., 2010) . It is a potentially disabling psychiatric disorder that can interfere with all aspects of life, such as work, school, and personal relationships. Even when controlling for symptoms of depression and anxiety, quality of life scores are lower in patients with OCD, particularly among female patients (Jahangard et al., 2017) .
The age at onset is bimodal, with peaks in late childhood or early adolescence and early adulthood (Anholt et al., 2014) .
Converging lines of evidence link OCD to abnormalities in the orbitofrontal cortex (OFC), anterior cingulate cortex (ACC), striatum, and thalamus (Milad and Rauch, 2012; Haber and Heilbronner, 2013) . Orbitofrontal cortex is functionally divided into two parts (Kringelbach and Rolls, 2004) : the lateral OFC is hyperactivated (during symptom provocation (Adler et al., 2000; Breiter et al., 1996) and proportionally to OCD symptom severity (Rauch et al., 2007) ) and the medial OFC is hypoactivated (inversely correlated with symptom severity) (Radua et al., 2010) . The dorsal anterior cingulate cortex (dACC) has also been implicated, proved not only by functional neuroimaging (Schlosser et al., 2010; Radua et al., 2010) and treatment studies (Perani et al., 1995) , but also by the decrease in OCD symptoms after anterior cingulotomy (Bourne et al., 2013; Dougherty et al., 2002) .
At the neurocircuit level, a combination of neuroimaging, neuropsychological and treatment studies have provided substantial evidence that the pathophysiology of OCD entails abnormal functioning along cortico-striato-thalamo-cortical (CSTC) pathways (Saxena and Rauch, 2000; Rauch et al., 2007; Swedo et al., 1989; Saxena et al., 1998; Cannistraro et al., 2004) . Activity in this circuit was elevated in the basal state, accentuated during symptom provocation (Rauch et al., 1994; Simon et al., 2010; McGuire et al., 1994) and nearly normal with successful treatment (Swedo et al., 1992; Baxter et al., 1992) .
At a neurotransmission level, serotonin seems to have an important role in the pathophysiology of OCD, essentially due to the discovery of selective serotonin reuptake inhibitors (SSRIs) efficacy in the treatment of OCD (Goddard et al., 2008) . In fact, brain imaging studies reported that certain regions in the brain have reductions in serotonin availability (Hasselbalch et al., 2007; Hesse et al., 2005; Stengler-Wenzke et al., 2004) . However, as mentioned above, only about half patients respond to treatment with SSRIs (Soomro et al., 2008) , concluding that an explanation based only on serotonin deficit couldn't completely illustrate the pathophysiology of this disease.
In addition to the serotonin transporter system, there is growing evidence that disrupted neurotransmission of glutamate, the main neurotransmitter within the CSTC, is implicated in the pathogenesis of OCD (Pittenger et al., 2011; Wu et al., 2012) . Research has shown significantly higher levels of glutamate in the cerebral spinal fluid and several sections of the brain, namely orbitofrontal cortex and caudate (Bhattacharyya et al., 2009; Yucel et al., 2008; Chakrabarty et al., 2005) , suggesting a role of glutamatergic hyperactivity and it's consequent excitotoxicity and oxidative stress, in the pathophysiology of OCD (Pittenger et al., 2011; Chakrabarty et al., 2005; Burdo et al., 2006; Chakraborty et al., 2009a) .
Oxidative stress is attested by lipid peroxidation and alterations to antioxidant systems in serum samples of these patients (Ersan et al., 2006; Ozdemir et al., 2009; Behl et al., 2010) . Symptom severity, as measured by Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score, seems to be correlated with increased levels of oxidative stress (Chakraborty et al., 2009a; Ozdemir et al., 2009; Chakraborty et al., 2009b) .
As OCD is a phenotypically heterogeneous disorder with a broad range of symptomatic expression (Pauls et al., 2014) , there has been increasing interest in identifying more uniform subtypes with distinct patterns of co-morbidities and outcomes .
American Psychiatric Association practice guidelines recommend cognitive-behavioral therapy (CBT) that involves exposure and response prevention, and selective serotonin reuptake inhibitors (SSRIs) as safe and effective first-line treatments for OCD. Despite the adequate treatment trials, 40% to 60% of patients preserve residual or impairing symptoms (Pallanti and Quercioli, 2006) and SSRIs are not free from adverse side effects. The severity and nature of adverse reactions associated with the use of SSRIs, particularly in the required higher doses, can often lead to treatment discontinuation. SSRIs can lead to adverse effects such as anxiety, insomnia, nausea, diarrhea, headache, constipation, dizziness, sedation, decreased libido and sexual dysfunction (Bloch et al., 2010; Papakostas, 2008; Jenike, 2004) . In addition to this, current antidepressant treatments need an extended waiting period, usually several weeks or even months, until the onset of symptom improvement (Jenike, 2001 ). Consequently, the investigation for more targeted pharmacologic agents and new augmentation strategies are crucial. In this way, some studies have been published focusing in the potential effect of other drugs, such as buprenorphine and memantine, and also non-pharmacological therapies, like electroconvulsive therapy (ECT), with auspicious results (Ahmadpanah et al., 2017; Haghighi et al., 2013; Manhas et al., 2016) . Regarding this matter, in 2006, Lafleur and colleagues (Bonanomi and Gazzaniga, 1980) found promising results with the use of N-acetylcysteine (NAC). In addition to these results, the excellent tolerability profile and low-cost of NAC, raised a large expectation around this pharmacological agent. It cannot be obtained through diet, therefore, supplements are the only source.
NAC is an acetylated precursor of the amino acid cysteine and has been widely used for its recognized ability as an antioxidant, by its metabolic contribution to glutathione (GSH) synthesis, in the treatment of acetaminophen overdose and as a mucolytic (Cotgreave, 1997) .
With oral administration, NAC is almost entirely converted to cysteine in the liver, which is mostly turned into GSH. Nevertheless, the remaining cysteine enters the systemic circulation and crosses the blood-brain barrier (Cotgreave, 1997) . Reaching the brain, cysteine is oxidized to cystine. Extracellular cystine is exchanged by intracellular glutamate by the cystine-glutamate antiporter (or x(c)-system), located mainly on glial cells in the brain (Pow, 2001) , thereby regulating extracellular glutamate levels and promoting cystine entry to the cell (Kau et al., 2008) . Inside the cell, cystine can be reduced to cysteine, which is the limiting reagent for GSH assembly (Cotgreave, 1997) .
NAC might exert its therapeutic effect on OCD through two main mechanisms.
First, NAC participates in the general antioxidant activities by its metabolic contribution to GSH production by providing an additional concentration of cysteine (Zafarullah et al., 2003; Atkuri et al., 2007) . Increased availability of GSH, scavenges toxic by-products of glutamatergic and dopamine metabolism, reducing oxidative and nitrosative stress, and thus cell damage (Berk et al., 2013) . (Fig. 1) .
Second, NAC modulates glutamatergic neurotransmission. The release of non-vesicular glutamate to extracellular space caused by NAC, activates group II metabotropic glutamate receptors (mGluR2/3). These receptors are predominantly presynaptic and negatively modulate the glutamatergic neurotransmission and excitotoxicity (Burdo et al., 2006; Berk et al., 2013) . (Fig. 1) .
The present work aimed to provide a systematic review of the Fig. 1 . Mechanism of action of NAC. When inside the brain, cysteine is oxidized to cystine. Extracellular cystine is exchanged by intracellular glutamate (Glu) by the cystine-glutamate antiporter (or x(c)-system), thereby regulating extracellular glutamate levels and promoting cystine entry to the cell. Inside the cell, cystine can be reduced to cysteine, which is the limiting reagent for GSH assembly. Non-vesicular glutamate in extracellular space, activates group II metabotropic glutamate receptors (mGluR2/3). These receptors negatively modulate the glutamatergic neurotransmission and excitotoxicity. (1.5 column fitting image).
current evidence available concerning the efficacy of NAC in the treatment of OCD.
Methods
A systematic review focusing on the efficacy of NAC on OCD was performed in accordance with PRISMA criteria (Moher et al., 2009 ).
Search strategy
An exhaustive literature search for publications regarding NAC in the treatment of OCD was conducted, until September 2017, in PUBMED, COCHRANE and SCIENCE DIRECT databases. Search algorithms were the following: (("acetycysteine" OR "n-acetylcysteine" OR "NAC") and "obsessive compulsive disorder") in PUBMED database, (("acetycysteine" OR "n-acetylcysteine") AND "obsessive compulsive disorder") in COCHRANE database, and (("acetycysteine" OR "n-acetylcysteine") AND ("obsessive compulsive disorder" OR "OCD")) in SCIENCE DIRECT. In the latter search the article subtypes included were research articles, conference abstracts, case reports, correspondence, discussion, news and short communications and other.
Eligibility criteria
The inclusion criteria were: (American Psychiatric Association, 2013) clinical trials and case reports studying the use of NAC in the treatment of OCD in adult and pediatric populations, (Brüne, 2015) studies investigating the therapeutic effect of NAC as either a standalone or adjunctive treatment, (Saxena and Rauch, 2000) articles written in English.
We excluded studies that (American Psychiatric Association, 2013) investigated an OCD-related disorder, as described by DSM-5, (Brüne, 2015) did not involve humans, (Saxena and Rauch, 2000) were systematic reviews.
Study selection and data collection process
Studies were screened and selected by two reviewers. First, all titles and abstracts were read, and the inclusion and exclusion criteria were applied by each reviewer independently. Second, the articles considered for inclusion after selection by title/abstract reading were read fully by the two authors, and the inclusion and exclusion criteria were applied again. Only the articles that were consensually accepted by the two reviewers were finally included. Data was extracted independently by one author (Couto, JP). The data collected from each study were: type of study, number of patients enrolled and mean age, co-morbidities of participants and concomitant medication, dose and duration of NAC treatment, outcome measures with respective baseline and endpoint scores.
Assessment of risk of bias in included studies
The two authors, José Couto and Ricardo Moreira, working independently, assessed risk of bias using the tool described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins and Green, 2011) . Quality assessment was based on the following domains: 1, random sequence generation (selection bias); 2, allocation concealment (selection bias); 3, blinding of participants and personnel (performance bias); 4, blinding of outcome assessment (detection bias); 5, incomplete outcome data (attrition bias); 6, selective reporting (reporting bias); 7, other bias.
Outcome and statistical analysis
We collected Y-BOCS scores at baseline and after intervention from the two case series included in our review (Yazici and Percinel, 2015; Van Ameringen et al., 2013) . SPSS software v. 25.0 was used to perform statistical analysis. Mean Y-BOCS score at baseline and after intervention was calculated. Additionally, a non-parametric test, the Wilcoxon Test, was performed to determine if there was a significant difference between Y-BOCS score at baseline and at endpoint. P -values were calculated two tailed and p < .05 was considered significant.
Data from RCTs was pooled for meta-analysis and Review Manager 5.3 software (Review Manager, Computer programme for Windows Version 5.3, The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, 2014) was used. The outcome of interest was the mean score of Y-BOCS in NAC treated patients comparing to placebo group, at the study endpoint. Mean difference (MD) and its corresponding 95% confidence interval (CI) was used to report the summary statistics of our outcome, as it is a continuous variable and all studies used the same scale. The I 2 statistic was used to assess the heterogeneity due to between-study variation. The test of overall effect was assessed using z statistics at p < .05. Additionally, effect size was calculated, whenever possible, by Cohen's d and the results are presented in Table 4 .
Level of evidence ratings
We provide a grade of recommendation (GOR) for the use of NAC in OCD based on the level of evidence (LOE) for each study. Using a wellestablished scale, Oxford Centre for Evidence-Based Medicine 2011 Levels of Evidence (Howick et al., 2011) , each study was individually assessed to determine the LOE, ranging from level 1 to 5 (Table 1 ). After assessing all identified studies, a GOR ranging from A (solid evidence) to D (limited, inconsistent or inconclusive evidence) was assigned (Table 2) .
Results

Search and study selection
A total of 250 articles were identified by our query. Of these, 8 papers were excluded for being repeated and 242 were considered for full text analysis. A total of 232 articles were excluded because they were review articles, were not performed in humans or included patients with OCD related disorders. Therefore, nine articles and one poster were included in our systematic review (Fig. 2) . Five of the included articles are double-blind, placebo-controlled trials, 3 are case reports and 2 are case series.
Figs. 3 and 4 provide a summary of the risk of bias. Afshar et al. presents a risk of a performance bias due to the sulphur smell of NAC effervescent tablets that could compromise the blinding of participants and/or personnel. Additionally, patients' comorbidities were not (Lafleur et al., 2006) (N = 1; LOE 4), was the first to report the benefits of NAC in OCD. A significant improvement in OCD symptoms was described in a 58-year-old woman with treatmentresistant OCD, by adding NAC to fluvoxamine therapy. Previously, this patient had not improved with other drugs and only had a partial response with 300 mg/day of fluvoxamine, therapy that she had been taking for the preceding 12 years. During the 13-week trial, the SSRI drug was maintained throughout the NAC treatment period. The dose used in this study was initiated at 600 mg per os (P.O.) daily and titrated upward to a total daily dosage of 3000 mg over seven weeks and maintained at this dose for the remaining six weeks. During the trial, there was an improvement on Yale-Brown Obsessive Compulsive Scale score (Y-BOCS). In the first week, was noticed a serious reduction in symptom severity, a drop of 8 points on the Y-BOCS scale (from a baseline score of 32 to 24). At the end of the study, the Y-BOCS score was reduced to 9, with an overall reduction of 22 points from the beginning of this therapeutic intervention. The patient continued treatment with the same dose of fluvoxamine and NAC, and after a 2-month follow-up visit improvements were consistent.
Later on, in 2013, Van Ameringen et al. (Van Ameringen et al., 2013 ) (N = 6; LOE 4) failed to demonstrate the efficacy of NAC add-on therapy in adult patients with treatment-resistant OCD. In five of the six patients included in this study, no significant improvement of OCD symptoms was reported. The NAC treatment was started at 500 mg daily and was titrated up, depending on the clinical response and tolerability, to a mean dosage at the endpoint of 2800 mg/day. One patient was lost to follow-up after six weeks, and the other five completed 12 weeks of treatment. These five had been taking 3000 mg/day of NAC for 4 weeks at the study endpoint. The overall mean change from baseline score, as measured in Y-BOCS, was −1.3, with only one patient responding to NAC treatment (defined as a Clinical Global Impression-Severity (CGI-I) score of 2 and a 35% reduction in Y-BOCS, at the endpoint), with an overall reduction of 9 (Y-BOCS of 26 at baseline, 17 at endpoint). Mean Y-BOCS score at baseline and at study endpoint was, respectively, 29.3 ± 3.4 and 28.0 ± 6.5. There was not a difference between mean Y-BOCS score at baseline and after intervention (p = .50).
Yazici et al. (Yazici and Percinel, 2014) (N = 1; LOE 4), in 2014, reported the recovery achieved by adding NAC to citalopram in a 15-year-old female with treatment-resistant OCD. The patient was supplemented with NAC, which was titrated from 600 mg to 2400 mg daily over six weeks and maintained for further 18 weeks, while treatment with 60 mg/day citalopram was continued. In 24 weeks, a significant drop in symptom severity was detected as measured by the Y-BOCS, with a baseline score of 37 reduced to 9. This is considered a "full response", according to Pallanti and Quercioli (Pallanti and Quercioli, 2006) response classification (decrease in YBOCS score > 35% and a CGI-S of 1 or 2).
More recently, in 2015, these authors have published a series of 5 case reports (Yazici and Percinel, 2015) (N = 5; LOE 4), also in pediatric age. All patients were initially treated with NAC 600 mg daily, as augmentation therapy. The NAC dosage was then titrated up, taking into consideration the clinical response and side effects, to a final dosage that varied from 1800 mg to 3000 mg. Four of the 5 participants showed significant improvement with NAC augmentation therapy, after 24 weeks follow-up. Two experienced "full response", as defined above; the other two patients entered "remission", considered when Y-BOCS score is < 16. The remaining patient, considered as a "non-responder", had a decrease in Y-BOCS score < 25% and CGI-S of 4. Mean Y-BOCS score at baseline and at study endpoint was, respectively, 37.6 ± 2.2 and 20.6 ± 10.1, with an overall mean change of −17. Y-BOCS score after NAC treatment was significantly lower comparing to baseline (p = .04). J.P. Couto, R. Moreira Progress in Neuropsychopharmacology & Biological Psychiatry 86 (2018) [245] [246] [247] [248] [249] [250] [251] [252] [253] [254] Saraiva et al. (Saraiva et al., 2015) (N = 1; LOE 4) described a complete remission of all symptoms in a 44-year-old man with resistant OCD, after NAC (1200 mg/day) augmentation to paroxetine and risperidone. No adverse side effects were reported.
We pooled the results from Lafleur et al. (2006), Yazici et al. (2014) , Van Ameringen et al. (2013) and Yazici et al. (2015) (n = 13) and determined mean Y-BOCS score before and after NAC treatment. Mean Y-BOCS score at baseline and after intervention was, respectively, 33.3 ± 4.8 and 22.2 ± 9.9. Patients after NAC treatment had a mean reduction in Y-BOCS of 11 points (p = .01). Despite this positive result, one must be cautious interpreting it because NAC dosage and time of treatment were not the same in all patients included in this analysis.
Clinical trials (Table 4)
To assess the efficacy and safety of NAC, as an augmentation treatment in patients with treatment-refractory OCD, Afshar et al. (Afshar et al., 2012 ) (N = 48; LOE 2b) performed a 12-week randomized, double-blind, placebo-controlled clinical trial. In this study, 48 adult patients, with mean age of 31 years, were randomized into two equal groups and treated with SSRIs, at the same dose as in the preintervention, plus either placebo or NAC. The intervention group was supplemented with 2400 mg NAC daily, which was titrated from 600 mg and doubled weekly considering the clinical improvement and tolerance. The effects of NAC in the reduction of Y-BOCS score were significant over time and in comparison with the placebo group. Likewise, significant improvement in symptom severity, as measured by mean Y-BOCS reduction, was noticed by the end of the eighth week to the end of the study. At study endpoint, the mean reduction in Y-BOCS score was 11 in the NAC group and 6 in control group. Fifty-three percent of NAC-treated patients evidenced a clinical response at the end of the study, defined as a ≥ 35% reduction in Y-BOCS score, which was significantly higher than the control group, in which 15% reach the same outcome (p = .013). Regarding side effects, NAC-treated participants experienced significantly higher rates of gastrointestinal adverse events.
In 2015, Sarris et al. (Sarris et al., 2015) (N = 44; LOE 2b) published the results of another randomized, double-blind, placebo-controlled clinical trial using a higher dose of NAC, 3000 mg/day (1500 mg twice daily), in OCD patients (with ≥16 points in Y-BOCS score, at baseline). In this 16-week study, NAC was titrated from 1000 mg/day and elevated 1000 mg weekly. The mean age of the 44 study participants was 37 years with the majority (70.5%) taking psychotropic drugs, over half (56.8%) having SSRI and about one third (29,5%) were utilizing adjunctive therapies. In term of results, an apparent effect was emerging by week 12, however, at the endpoint, this study failed to show a significant time x treatment interaction for Y-BOCS total score. Despite this, a significant time x treatment interaction was described for the Y-BOCS compulsions subscale in NAC group, with a significant reduction detected at the twelfth week, although dissipated at the sixteenth. Overall, at week 16, 20% of NAC-treated patients evidenced a clinical response, defined as a ≥ 35% reduction in Y-BOCS score, compared with 27% in placebo group. NAC was well-tolerated with no differences in the total adverse events between the groups. Nevertheless, heartburn was the only clinical adverse event experienced in significantly higher rates in NAC group.
One year later, the same authors (Sarris et al., 2016) explored this data further and released an analysis of potentially modifying factors, such as age, severity and duration of illness, OCD presentation type, baseline anxiety and depression score and the use of antidepressant medications. They concluded that NAC is more effective in younger people with a shorter duration of OCD diagnosis.
Paydary et al. (Paydary et al., 2016 ) (N = 44; LOE 2b) performed a ten-week randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of NAC as an augmentation therapy compared to fluvoxamine monotherapy. In this work, 44 adult patients, with moderate to severe OCD (≥21 in Y-BOCS score), were randomized into two identical groups and treated with a SSRI (200 mg/day of fluvoxamine), plus either placebo or NAC. All patients took fluvoxamine 100 mg/day in the first four weeks and 200 mg/day for the rest of the study. The NAC group was supplemented with 2000 mg NAC daily (1000 mg bid), which was titrated from 1000 mg (500 twice daily) and doubled in the first week. Results analysis revealed a significant time x treatment interaction for the Y-BOCS total score and the Y-BOCS obsession subscale score. The difference between mean scores of Y-BOCS total score, Y-BOCS obsession subscale score, and Y-BOCS compulsion subscale score was not significant between the two groups at each time point of the trial. Furthermore, 12 NAC-treated participants accomplished remission (Y-BOCS score at the endpoint ≤16), compared to 5 patients in the control group, which was almost significant (p = .062). Regarding side effects, NAC-treated participants did not experience significantly higher rates of adverse events.
Ghanizadeh and colleagues (Ghanizadeh et al., 2017) (N = 34; LOE 2b) conducted a randomized, double-blind, placebo-controlled trial to evaluate the possible effects of NAC as an augmentation therapy compared to citalopram monotherapy in the treatment of children and adolescents (10 to 21 years) with OCD. In this 10-week trial, 34 patients were randomized into two groups to receive citalopram (20 to 40 mg/ day) plus placebo or citalopram (20 to 40 mg/day) plus NAC (titrated up to 2400 mg/day over six weeks). Results showed a significant decrease in the Y-BOCS score in the NAC-treated group from the fourth week to the end of the trial. In fact, the Y-BOCS score decreased from 21 to 11 in the NAC group during this study. Also, the Y-BOCS score at the end of the trial was significantly different between the two groups. The mean difference of Y-BOCS score was not statistically different between the two groups, at each time point of the trial. The mean score of change for "resistance/control to compulsion"-the sum of items 9 and Fig. 4 . Methodological quality graph.
J.P. Couto, R. Moreira
Progress in Neuropsychopharmacology & Biological Psychiatry 86 (2018) 245-254 Table 3 Case reports and case series. Table 4 Clinical trials. 10 scores of Y-BOCS -in NAC group was significantly higher compared to placebo. Regarding side effects, there was no statistical difference between groups. The most recent randomized, double-blind, placebo-controlled trial evaluating the effectiveness of NAC as an SSRI augmentation treatment was conducted by Costa et al. (Costa et al., 2017) (N = 40; LOE 2b) . In this trial, an adult treatment-resistant cohort of 40 patients, with a mean age of 38 years, was randomized to NAC (dose titrated from 1200 mg/day to a maximum of 3000 mg/day over two weeks) and placebo. All participants were concomitantly taking at least an SSRI, by international OCD treatment guidelines (Koran et al., 2007; Bandelow et al., 2012) . The obtained results demonstrated a non-significant difference in Y-BOCS scores between groups at the end of the study. A significant reduction in Y-BOCS score was noticed in NAC treated group over time. However, the control group showed an identical improvement. In a secondary analysis, patients treated with NAC had a significant reduction in anxiety, as measured by Beck Anxiety Inventory (BAI) score, compared to placebo group. The frequency of adverse events did not differ significantly between groups, except for "stomach/ abdominal pain".
The RCT from Paydary et al. was not included in the meta-analysis because it did not report standard deviation. There was a high statistical heterogeneity (I 2 = 65%), so a random effects meta-analysis was conducted. Considering the four RTCs (Fig. 5) pooled mean difference in Y-BOCS score at study endpoint was 3.35, and albeit not statistically significant it shows a favorable trend toward significance (95% CI -0.21-6.91, p = .07). Considering the pooled results from the four RCTs, patients treated with placebo have a mean Y-BOCS score at study endpoint that is approximately 3 points higher than patients treated with NAC. Furthermore, we present Cohen's d value in Table 4 , whenever it was possible to calculate. According to Sawilowsky (Sawilowsky, 2009) , Sarris et al. and Costa et al. RCTs have a very small effect size, whereas Ghanizadeh has a large/very large effect size.
Discussion
In a field where current treatments are limited, have suboptimal efficiency and an extensive spectrum of side effects, the search for alternatives is essential. Some authors suggest that NAC, due to its antioxidant effects and glutamatergic neurotransmission modulation, may be a promising pharmacological treatment for OCD. We systematically reviewed all published studies (in English) up to date assessing the efficacy of NAC in OCD, including clinical trials, case series and case reports.
Since the first case report in 2006 (Lafleur et al., 2006) , five clinical trials, 2 case reports, and 2 case series have been published. All case reports and case series demonstrated a marked improvement in symptoms with NAC augmentation therapy, except that carried out by Van Ameringen et al. (Van Ameringen et al., 2013) This failure could be attributable to the short duration of NAC intake at the maximum dose (4 weeks) and the existence of comorbid diagnosis, other than depression. Moreover, one should always keep in mind that therapeutic adherence is a relevant issue in these type of patients. Particularly in this case series, the authors have not objectively verified the adherence to an adequate treatment regimen. In the other studies, similar problems could have also occurred. However, compliance may have been more accurate since the patient in the Lafleur et al. case report (Lafleur et al., 2006) was at the inpatient unit throughout the treatment and the other two studies were conducted on children under parental care.
On the other hand, several factors may have contributed to an overestimation of the effect of NAC in the studies mentioned above. In fact, concomitant treatments, either pharmacological or non-pharmacological, could also have elicited symptoms amelioration. For example, the patient of Lafleur et al. (Lafleur et al., 2006) was hospitalized during the treatment period, receiving supportive psychotherapy, which was not a formal or manual driven cognitive-behavioral treatment plan but may have positively influenced the results. It is also important to note that in "case 1" of Yazici et al. (Yazici and Percinel, 2015) , the introduction of NAC was made only after four weeks of the increase of citalopram and this drug could have elicited its full response during the study.
The accurate classification of symptoms at baseline and after the intervention, by using a well stablished scale like Y-BOCS, is a crucial step. In the case report from Saraiva et al. (Saraiva et al., 2015) no obsessive symptom rating scale was used and the "classification" of the symptomatic improvement was based on the patient's interview and report. This lapse could obscure the plausibility of their conclusions.
The five clinical trials included in this review showed non-consensual results; 3 of them proclaimed NAC as a promising therapy in OCD patients. After the full analysis of their methodologies, we could delineate some aspects that can justify their differences.
In Afshar et al. (Afshar et al., 2012) , Paydary et al. (Paydary et al., 2016) and Ghanizadeh et al. (Ghanizadeh et al., 2017 ) the concomitant medication used during NAC supplementation was composed of only one drug, in particular, an SSRI. The other two studies used different concomitant psychotropic drugs between participants and in Sarris et al. (Sarris et al., 2015) NAC was used in monotherapy in 29.5% of patients.
Apparently, the existence of comorbidities may mitigate the therapeutic effects of NAC in OCD. In Sarris et al. (Sarris et al., 2015) almost 60% of patients had a comorbid psychiatric disorder, and in Costa et al. (Costa et al., 2017) only 22.5% suffered only from OCD. It would be important to know the specific psychiatric comorbidities. Nevertheless, some clinical trials did not record any information about comorbidities in their participants. The clinical trials in which patients have the higher mean age are the same that have not achieved significant positive outcomes. However, we have to keep in mind that older patients may also be the ones with longer disease duration. Hence, this factor, and not the age itself, can be the real modifying factor for NAC efficacy. This possibility was suggested in a post hoc analysis of the clinical trial conducted by Sarris et al. (Sarris et al., 2016) As discussed above, compliance is a problem in OCD patients. In the clinical trial of Sarris et al. (Sarris et al., 2015) a 75% tablet consumption rate was considered to be the minimum threshold for compliance. Therefore, the low response rate reported could be attributable Fig. 5 . Forest plot of mean difference (MD) by random effects model.
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Progress in Neuropsychopharmacology & Biological Psychiatry 86 (2018) 245-254 to the suboptimal patient compliance. In addition, treatment duration is still not clearly defined but it can be an aspect that influences response to NAC augmentation therapy.
We may not forget that OCD has a heterogeneous neurobiology nature. Therefore, the efficacy of NAC could be limited to a subset of people with polymorphisms in glutamate genes. Additionally, the necessary NAC dose to perform its neurobiological functions could be different for a subset of patients.
Ghanizadeh et al. (Ghanizadeh et al., 2017) and Sarris et al. (Sarris et al., 2015) demonstrated a higher reduction in compulsions compared to obsessions. However, Paydary et al. (Paydary et al., 2016) showed the opposite results. For this reason, efforts must be made to explore whether NAC may exert a preferential effect on compulsions or obsessions.
Future clinical trials need to address some important methodological issues to provide more definitive answers regarding the benefits of NAC for OCD. Sample size calculation is a crucial step when designing a study. Considering a difference between endpoint and baseline total Y-BOCS scores of 5 points (presumed the minimal difference with clinical significance), an estimated standard deviation of 6.0 based on previous studies, a power of 85% (the value assumed in most medical literature varies from 80 to 90%), and an α of 5%, the sample size should be 52 participants (26 per arm). Of the five RCTs included in this review, Afshar et al. study was the one with the nearest sample size (n = 48) but 9 patients have discontinued treatment so only 39 patients were analysed at study endpoint. It would also be important to have a better characterization of the participants included in the study, namely the mean age, mean duration of disease and symptom dimensions. Additionally, trials may also need longer follow-up times, as it is not clear the NAC latency time for efficacy and if this effect can be maintained over time. It would be important to sustain the follow-up for some time after discontinuation of NAC, in order to detect symptom relapsing. Dose-finding studies are still a need, as it remains to be demonstrated if higher doses correlate with greater efficacy.
Future research with magnetic resonance imaging (MRI) or functional MRI brain imaging would also be important, in order to understand in more detail what are the specific effects of NAC in brain activity that contribute to reduce symptoms in some patients and, consequently, expand the knowledge of the pathophysiology of this disease.
The beneficial effects of NAC could also be limited by its low bioavailability. Therefore esterification of the carboxyl group of NAC to produce N-acetylcysteine ethyl ester (NACET) would enhance its lipophilicity and, consequently, its pharmacokinetics (Giustarini et al., 2012) . In this way, NACET could be employed in future clinical trials as it holds the potential to be more effective than NAC.
As we expected, NAC used in doses ranging from 1200 mg to 3000 mg, has proved an optimal tolerability profile and the most frequently reported adverse events were gastrointestinal, specially diarrhea. Indeed, it may also have clinical utility, as it can counterbalance constipation caused by other psychopharmaceuticals commonly used in OCD treatment. This information is in accordance with previous research using NAC for other diseases. In fact, De Rosa et al. (De Rosa et al., 2000) showed that doses up to 8000 mg/day are not known to cause any clinically significant adverse reaction.
Regarding the level of evidence of the studies included in this systematic review, and the fact that some of these studies have not proven the efficacy of NAC in the treatment of OCD, we consider that the GOR for using this pharmacological agent in the treatment of OCD is D. Notwithstanding this low GOR, our pooled result from 4 of the five RCTs included, trends to favour the use of NAC over placebo, with a pvalue in the verge of significance.
Conclusion
We would expect NAC to have a beneficial effect on OCD symptoms due to what is known about the pathophysiology of OCD. However, up to now, there are contradictory results.
In this way, despite the degree of evidence being D, our opinion is that the potential value of NAC is being underestimated. Considering the level of disability caused by resistant OCD, and the exceptional tolerability profile of NAC, its use as an add-on agent should be contemplated, on an ad hoc basis.
It is essential to consider further studies to better elucidate the potential role of NAC in the treatment of OCD.
